In addition, B7-H3 (CD276), a type I transmembrane protein, is generally expressed at low levels in normal tissues but is overexpressed in a wide variety of cancers, including gastric cancer, pancreatic cancer, neuroblastoma, endometrial cancer, glioma, melanoma, lung cancer, ovarian carcinomas, and prostate cancer, positioning B7-H3 as a promising immunotherapeutic target. This evidence concerns the gene CD276 and lung carcinoma.